Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
Published: 14:59 13 Jul 2026 EDT
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector.
The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.
For companies developing psychedelic-based therapies, the guidance provides greater clarity on the FDA's expectations for clinical development and trial design, while signaling continued agency engagement with sponsors as late-stage programs progress.
"Ultimately, a friendlier regulatory environment should make psychedelics a more investable space," Jefferies wrote.
The hearing will seek public feedback on issues related to psychedelic drugs administered in supervised or supportive settings. The FDA said the event will support implementation of a presidential executive order directing the Department of Health and Human Services and the agency to coordinate with other federal partners on psychedelic therapies.
According to the FDA, discussion topics will include provider training and credentialing, patient safety, access considerations, and best practices for data collection and standardization. The hearing will be informal, with questions limited to FDA officials and participating federal panelists, while members of the public may submit comments.
Jefferies noted the timing of the hearing comes as Compass Pathways (NASDAQ:CMPS)' COMP360 oral psilocybin program could become the first psychedelic therapy approved by the FDA around the end of 2026.
The firm said it wonders whether the public hearing could reduce the need for future advisory committee meetings unless clinical data prove controversial.
The finalized guidance expands on the FDA's 2023 draft by placing greater focus on generating interpretable efficacy data and strengthening trial integrity. The agency outlined a more flexible, risk-based approach to nonclinical studies, updated recommendations on evaluating abuse potential using computational models, and additional measures to address functional unblinding and expectancy bias in clinical trials. The guidance also places greater emphasis on demonstrating long-term durability of treatment effects and includes new safety recommendations.
Jefferies said the broader backdrop for psychedelic drug development continues to improve, citing growing pharmaceutical industry interest, the commercial success of Johnson & Johnson (NYSE:JNJ)'s Spravato and increasing regulatory collaboration.
The firm added that a more amenable FDA could lower regulatory uncertainty across the sector, supporting investment in companies developing psychedelic therapies for conditions including major depressive disorder, treatment-resistant depression, post-traumatic stress disorder and social anxiety disorder.
